scispace - formally typeset
I

Ina van Zantwijk

Researcher at VU University Medical Center

Publications -  10
Citations -  485

Ina van Zantwijk is an academic researcher from VU University Medical Center. The author has contributed to research in topics: Bortezomib & PSMB5. The author has an hindex of 5, co-authored 10 publications receiving 458 citations. Previous affiliations of Ina van Zantwijk include VU University Amsterdam.

Papers
More filters
Journal ArticleDOI

Drug combination testing in acute lymphoblastic leukemia using the MTT assay

TL;DR: The MTT assay can be used to study drug interactions in vitro in ALL samples with marked heterogeneity in drug interactions between patients, between combinations, and between different concentrations within one specific combination.
Journal ArticleDOI

Diagnosis of meningeal leukemia using immunoperoxidase methods to demonstrate common acute lymphoblastic leukemia cells in cerebrospinal fluid.

TL;DR: This study focussed on the presence of the common acute lymphoblastic leukemia marker (cALL, determined with the monoclonal antibody J5), which was found to be an invaluable aid to the diagnosis of meningeal leukemia.
Journal ArticleDOI

Folates provoke cellular efflux and drug resistance of substrates of the multidrug resistance protein 1 (MRP1)

TL;DR: It is demonstrated that increased cellular folate concentrations induce MRP1/ABCC1-related drug efflux and drug resistance, and has important implications in the understanding of the role of MRp1 and its homologs in clinical drug resistance.
Journal ArticleDOI

Molecular Mechanisms of Bortezomib Resistance in Acute Lymphoblastic Leukemia Cells in Comparison with Multiple Myeloma Cells.

TL;DR: The results demonstrate that BTZ exhibits potent activity against CEM-ALL and 8226 MM cells, and suggest that MM cells largely retain BTZ sensitivity upon prolonged exposure to BTZ, while in ALL drug resistance phenomena may be more likely to occur.